Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. 1986

R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins

A cDNA clone representing the mRNA coding sequence of the fusion glycoprotein (F) gene of human respiratory syncytial virus (RSV) was constructed and inserted into the thymidine kinase gene of vaccinia virus (WR strain) under the control of a vaccinia virus promoter. The resulting recombinant vaccinia virus, vaccinia F, expressed the F1 and F2 cleavage products (48 and 20 kDa, respectively) of the F glycoprotein in cell culture. F1 and F2 were indistinguishable from their authentic RSV counterparts with respect to glycosylation, disulfide linkage, electrophoretic mobility, cell-surface expression, and antigenic specificity. Cotton rats infected intradermally with vaccinia F developed a high titer of serum F-specific antibodies, which neutralized infectivity of RSV. This neutralizing antibody response exceeded that induced by infection of the respiratory tract with RSV and was 6-fold higher than that induced by vaccinia G, a recombinant vaccinia virus that expressed the RSV G glycoprotein gene. Immunization with vaccinia F stimulated almost complete resistance to replication of RSV in the lower respiratory tract as well as significant resistance in the upper respiratory tract. The degree of resistance conferred by vaccinia F exceeded that induced by vaccinia G.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D012136 Respiratory Syncytial Viruses A group of viruses in the PNEUMOVIRUS genus causing respiratory infections in various mammals. Humans and cattle are most affected but infections in goats and sheep have also been reported. Chimpanzee Coryza Agent,Orthopneumovirus,RSV Respiratory Syncytial Virus,Chimpanzee Coryza Agents,Coryza Agent, Chimpanzee,Orthopneumoviruses,Respiratory Syncytial Virus,Syncytial Virus, Respiratory,Virus, Respiratory Syncytial
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D003411 Arvicolinae A subfamily of MURIDAE found nearly world-wide and consisting of about 20 genera. Voles, lemmings, and muskrats are members. Clethrionomys,Cricetidae,Dicrostonyx,Lemmings,Lemmus,Mice, Red-Backed,Microtinae,Microtus,Muskrats,Ondatra,Voles,Arvicolines,Microtines,Mouse, Red-Backed,Myodes,Ondatra zibethicus,Arvicoline,Lemming,Mice, Red Backed,Microtine,Mouse, Red Backed,Muskrat,Red-Backed Mice,Red-Backed Mouse,Vole
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen
D014614 Vaccines, Synthetic Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified. Antigens, Synthetic,Chemical Vaccine,Chemical Vaccines,Immunogens, Synthetic,Molecular Vaccine,Molecular Vaccines,Recombinant Vaccine,Semisynthetic Vaccine,Semisynthetic Vaccines,Synthetic Antigen,Synthetic Vaccine,Synthetic Vaccines,Vaccines, Recombinant,Synthetic Antigens,Synthetic Immunogens,Vaccines, Chemical,Vaccines, Molecular,Vaccines, Semisynthetic,Antigen, Synthetic,Recombinant Vaccines,Vaccine, Chemical,Vaccine, Molecular,Vaccine, Recombinant,Vaccine, Semisynthetic,Vaccine, Synthetic
D014616 Vaccinia virus The type species of ORTHOPOXVIRUS, related to COWPOX VIRUS, but whose true origin is unknown. It has been used as a live vaccine against SMALLPOX. It is also used as a vector for inserting foreign DNA into animals. Rabbitpox virus is a subspecies of VACCINIA VIRUS. Buffalopox virus,Poxvirus officinale,Rabbitpox virus,Buffalo Pox Virus,Rabbit Pox Virus,Buffalo Pox Viruses,Buffalopox viruses,Rabbit Pox Viruses,Rabbitpox viruses,Vaccinia viruses,Virus, Buffalo Pox,Viruses, Buffalo Pox,virus, Buffalopox
D014760 Viral Fusion Proteins Proteins, usually glycoproteins, found in the viral envelopes of a variety of viruses. They promote cell membrane fusion and thereby may function in the uptake of the virus by cells. Fusion Proteins, Viral,Viral Fusion Glycoproteins,F Protein (Sendai Virus),F Protein Measles Virus,F Protein Newcastle Disease Virus,F Protein SV,F-Glycoprotein SV,F1 Polypeptide (Paramyxovirus),Fusion Glycoprotein, Viral,Fusion VP1 Protein,Glycoprotein, Viral Fusion,Measles Fusion Protein,Mumps Virus Fusion Protein,Paramyxovirus Fusion Protein,Sendai Virus Fusion Protein,Viral Fusion-GP,Virus Fusion Proteins,Fusion Glycoproteins, Viral,Fusion Protein, Measles,Fusion Protein, Paramyxovirus,Fusion Proteins, Virus,Fusion-GP, Viral,Glycoproteins, Viral Fusion,Proteins, Virus Fusion,VP1 Protein, Fusion,Viral Fusion GP,Viral Fusion Glycoprotein

Related Publications

R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
November 1987, Journal of virology,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
January 1986, Proceedings of the National Academy of Sciences of the United States of America,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
October 1987, Journal of virology,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
October 1999, Vaccine,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
October 1988, Journal of virology,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
November 1986, Journal of virology,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
March 1986, Proceedings of the National Academy of Sciences of the United States of America,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
October 2006, FEMS immunology and medical microbiology,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
April 1987, Journal of clinical microbiology,
R A Olmsted, and N Elango, and G A Prince, and B R Murphy, and P R Johnson, and B Moss, and R M Chanock, and P L Collins
December 1988, Vaccine,
Copied contents to your clipboard!